Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 5:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 720 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Dry Eye Disease Clear all
Completed Phase 3 Interventional Results available

Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)

NCT04005352
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
Brolucizumab 6 mg, Aflibercept 2 mg
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
734 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
24
States / cities
Phoenix, Arizona • Huntington Beach, California • Loma Linda, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 5, 2026, 5:53 AM EDT
Completed Not applicable Interventional Results available

e-Mobile Tablet for People With Chronic Conditions

NCT02833311
View directory record Official record
Conditions
Fibromyalgia, Multiple Sclerosis, Osteoarthritis, Sjögren's Syndrome, Parkinson's Disease
Interventions
Computer Tablet Group, Paper and Pencil Group, Contact Control Group
Behavioral
Lead sponsor
Case Western Reserve University
Other
Eligibility
18 Years to 76 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 12, 2023 · Synced Oct 5, 2026, 5:53 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Tear Osmolarity Changes After Instilling Isotonic Hyaluronate Artificial Tears

NCT01614847
View directory record Official record
Conditions
Dry Eye
Interventions
Artificial tears
Drug
Lead sponsor
Thomas O Salmon, OD, PhD
Other
Eligibility
18 Years to 35 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Tahlequah, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 3, 2020 · Synced Oct 5, 2026, 5:53 AM EDT
Completed Phase 1Phase 2 Interventional

Safety and Tolerability of Sub-retinal Transplantation of hESC Derived RPE (MA09-hRPE) Cells in Patients With Advanced Dry Age Related Macular Degeneration

NCT01344993
View directory record Official record
Conditions
Dry Age Related Macular Degeneration
Interventions
MA09-hRPE
Biological
Lead sponsor
Astellas Institute for Regenerative Medicine
Industry
Eligibility
55 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
4
States / cities
Los Angeles, California • Miami, Florida • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Oct 5, 2026, 5:53 AM EDT
Withdrawn Phase 4 Interventional

A Phase IV, Randomized, Parallel Group, Investigator-Masked Evaluation of the Effect of Loteprednol Etabonate Ophthalmic Gel 0.5% on the Initiation of Dry Eye Treatment With Restasis®

NCT02028312
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Loteprednol etabonate, Artificial Tears, Restasis
Drug
Lead sponsor
Edward Holland, MD
Other
Eligibility
21 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Edgewood, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 18, 2015 · Synced Oct 5, 2026, 5:53 AM EDT
Completed Phase 3 Interventional Results available

Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2

NCT02974907
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
RGN-259, Placebo
Drug
Lead sponsor
ReGenTree, LLC
Industry
Eligibility
18 Years and older
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 5, 2022 · Synced Oct 5, 2026, 5:53 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers Results available

Prevalence of Dry Eyes in Diabetics Compared to Non Diabetics

NCT01450787
View directory record Official record
Conditions
Dry Eyes
Interventions
Not listed
Lead sponsor
COA Research Foundation, INC
Other
Eligibility
40 Years and older
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 30, 2013 · Synced Oct 5, 2026, 5:53 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of the Safety and Efficacy of OmegaD Softgels in the Treatment of Dry Eye Disease

NCT04181593
View directory record Official record
Conditions
Dry Eye
Interventions
Omega 3 fatty acid, Placebos
Drug
Lead sponsor
OmegaD LLC
Industry
Eligibility
18 Years to 90 Years
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
14
States / cities
Newport Beach, California • Westminster, California • Largo, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Oct 5, 2026, 5:53 AM EDT
Completed No phase listed Observational Results available

Physician's Evaluation of Cyclosporine Ophthalmic Emulsion 0.05%

NCT00827255
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Cyclosporine Ophthalmic Emulsion 0.05%
Drug
Lead sponsor
Allergan
Industry
Eligibility
16 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 25, 2019 · Synced Oct 5, 2026, 5:53 AM EDT
Completed Not applicable Interventional Results available

Acute Tear Production Following Single Use of the Oculeve Intranasal Neurostimulator

NCT02798289
View directory record Official record
Conditions
Dry Eye Syndrome, Keratoconjunctivitis Sicca
Interventions
Oculeve Intranasal Neurostimulator
Device
Lead sponsor
Oculeve, Inc.
Industry
Eligibility
22 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
2
States / cities
Artesia, California • Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Oct 25, 2017 · Synced Oct 5, 2026, 5:53 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy Assessment of Vismed® (Sodium Hyaluronate) for the Treatment of Dry Eye Syndrome

NCT00599716
View directory record Official record
Conditions
Dry Eye Disease
Interventions
sodium hyaluronate, vehicle
Drug
Lead sponsor
Lantibio
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
10
States / cities
Boynton Beach, Florida • Miami, Florida • Stuart, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2009 · Synced Oct 5, 2026, 5:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Treating Contact Lens Discomfort With Orthokeratology

NCT03566680
View directory record Official record
Conditions
Dry Eye, Contact Lens Complication
Interventions
Orthokeratology
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 45 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 17, 2020 · Synced Oct 5, 2026, 5:53 AM EDT
Completed Phase 1 Interventional

Study Evaluating Techniques for Measuring Tear Production

NCT05497479
View directory record Official record
Conditions
Dry Eye Disease
Interventions
0.003% AR-15512 to be administered in both eyes, Vehicle to be administered in both eyes
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2022 · Synced Oct 5, 2026, 5:53 AM EDT
Completed No phase listed Observational

An Observational Study to Assess Optive MEGA-3 (OM3) on Dry Eye Symptoms and Quality of Life of Adult Participants With Mild to Moderate Dry Eye Disease (DED)

NCT06439394
View directory record Official record
Conditions
Dry Eye
Interventions
Optive MEGA-3 (OM3)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Oct 5, 2026, 5:53 AM EDT
Terminated Phase 4 Interventional

Xiidra vs. Xiidra + Dextenza Treatment for Dry Eye Disease

NCT04413253
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Lifitegrast 5% Ophthalmic Solution, Dexamethasone Intracanalicular Insert, 0.4mg with Lifitegrast 5% Ophthalmic Solution
Drug
Lead sponsor
Eye Surgeons of Indiana
Network
Eligibility
Not listed
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 18, 2022 · Synced Oct 5, 2026, 5:53 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Meibomian Gland Probing in the Sub-Acute Phase of Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis

NCT05145959
View directory record Official record
Conditions
Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses, Ocular Surface Disease, Meibomitis, Meibomian Gland Dysfunction, Dry Eye
Interventions
Maskin Probe
Device
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 6, 2021 · Synced Oct 5, 2026, 5:53 AM EDT
Completed Not applicable Interventional Results available

Effectiveness of Intense Pulsed Light for Improving Dry Eye Syndrome

NCT03396913
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
IPL, Sham IPL, MGX
Device · Procedure
Lead sponsor
Lumenis Be Ltd.
Industry
Eligibility
22 Years to 85 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Nashville, Tennessee • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 9, 2020 · Synced Oct 5, 2026, 5:53 AM EDT
Completed Phase 3 Interventional

A Safety and Efficacy Study of MIM-D3 Ophthalmic Solution for the Treatment of Dry Eye

NCT01960010
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
MIM-D3 Ophthalmic Solution, Vehicle
Drug
Lead sponsor
Mimetogen Pharmaceuticals USA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
403 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
5
States / cities
Waterbury, Connecticut • Lewiston, Maine • Andover, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Oct 5, 2026, 5:53 AM EDT
Completed Phase 2 Interventional Results available

Study of VVN001 Ophthalmic Solution in Dry Eye Disease

NCT04556838
View directory record Official record
Conditions
Dry Eye
Interventions
VVN001 Ophthalmic Solution 1%, VVN001 Ophthalmic Solution 5%, Vehicle
Drug
Lead sponsor
VivaVision Biotech, Inc
Industry
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Oct 5, 2026, 5:53 AM EDT
Completed Phase 2Phase 3 Interventional Results available

The TRANQUILITY Trial: Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease

NCT04674358
View directory record Official record
Conditions
Dry Eye, Dry Eye Syndromes
Interventions
Reproxalap Ophthalmic Solution (0.25%), Vehicle Opthalmic Solution
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Oct 5, 2026, 5:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

TrueTear in Sjogren's Disease Patients

NCT03719885
View directory record Official record
Conditions
Dry Eye Syndromes, Sjogren's Syndrome
Interventions
TrueTear Intranasal Tear Neurostimulator
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
22 Years and older
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 7, 2023 · Synced Oct 5, 2026, 5:53 AM EDT
Terminated Phase 2 Interventional Results available

Phase 2 Study of a New Ophthalmic Formulation of Cyclosporine (Restasis® X) in Patients With Dry Eye Disease

NCT02013791
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Vehicle, Sham, Cyclosporine New Ophthalmic Formulation
Drug · Other
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
8
States / cities
Artesia, California • Glendale, California • Irvine, California + 5 more
Source: ClinicalTrials.gov public record
Updated May 15, 2018 · Synced Oct 5, 2026, 5:53 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Evaluation of Screening Methods for Treatment of Meibomian Gland Dysfunction

NCT01202747
View directory record Official record
Conditions
Chalazion, Dry Eye Syndromes
Interventions
LipiFlow System
Device
Lead sponsor
TearScience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
3
States / cities
Hoffman Estates, Illinois • Boston, Massachusetts • Winchester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 6, 2011 · Synced Oct 5, 2026, 5:53 AM EDT
Completed Phase 4 Interventional

A Phase 4 Study Investigating the Efficacy of Retaine™ in Managing Signs and Symptoms Associated With Dry Eye Syndrome

NCT02139033
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
Retaine™
Drug
Lead sponsor
Ocusoft, Inc.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 11, 2014 · Synced Oct 5, 2026, 5:53 AM EDT